Investment Thesis
Mangoceuticals faces severe operational distress with collapsing revenues (-26% YoY), massive operating losses (-$18M on $456K revenue), and negative free cash flow of -$5.9M. The company is burning cash at an unsustainable rate with only $1.5M in cash reserves, indicating imminent solvency concerns without significant operational turnaround or capital infusion.
Strengths
- Decent gross margin of 54.9% suggests product economics are viable at scale
- Minimal debt burden with 0.00x debt-to-equity ratio and $890.6K total liabilities
- Current ratio of 1.74x indicates adequate short-term liquidity position
Risks
- Revenue in severe decline (-26% YoY) with extremely low absolute revenue ($456K) indicating minimal market traction
- Catastrophic cash burn of -$5.9M in operating cash flow relative to $1.5M cash reserves suggests runway of ~3 months
- Operating margin of -3954% and net margin of -4526% reflect fundamental business model failure with expenses drastically exceeding any revenue generation
- Negative ROE and ROA both below -128% demonstrate complete destruction of shareholder value
- Minimal insider confidence with only 2 Form 4 filings in 90 days
Key Metrics to Watch
- Monthly cash burn rate and cash runway until depletion
- Revenue trend stabilization or further deterioration
- Success of cost reduction initiatives to achieve operating cash flow positive status
- Any capital raises or debt financing announcements indicating survival strategy
Financial Metrics
Revenue
456.0K
Net Income
-20.6M
EPS (Diluted)
$-2.17
Free Cash Flow
-5.9M
Total Assets
16.1M
Cash
1.5M
Profitability Ratios
Gross Margin
54.9%
Operating Margin
-3,954.3%
Net Margin
-4,526.8%
ROE
-135.8%
ROA
-128.3%
FCF Margin
-1,283.7%
Balance Sheet & Liquidity
Current Ratio
1.74x
Quick Ratio
1.72x
Debt/Equity
0.00x
Debt/Assets
5.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-01T22:08:11.650916 |
Data as of: 2025-12-31 |
Powered by Claude AI